Revenue and Profitability - Revenue increased by $4.4 million, or 31%, to $18.9 million for the three months ended November 30, 2024, compared to $14.5 million for the same period in 2023[123] - Gross profit increased by $0.4 million, or 4%, to $10.2 million for the three months ended November 30, 2024, compared to $9.8 million for the same period in 2023[125] - Net income decreased by $1.7 million, or 89%, to $0.2 million for the three months ended November 30, 2024, compared to $1.9 million for the same period in 2023[125] Expenses - Research and development costs increased by $0.4 million, or 19%, to $2.6 million for the three months ended November 30, 2024, compared to $2.2 million for the same period in 2023[129] - Sales and marketing expenses increased by $0.9 million, or 43%, to $2.9 million for the three months ended November 30, 2024, compared to $2.0 million for the same period in 2023[130] - Stock-based compensation costs were $1.7 million for the three months ending November 30, 2024, compared to $1.3 million in 2023[166] Cash Flow and Investments - Net cash used in operating activities was $1.3 million for the three months ended November 30, 2024, compared to net cash provided of $0.2 million for the same period in 2023[138] - Net cash used in investing activities was $3.1 million for the three months ended November 30, 2024, compared to $16.9 million for the same period in 2023[141] - Cash, cash equivalents, and short-term investments totaled $18.2 million as of November 30, 2024[137] Acquisitions and Obligations - The Company acquired Pro-ficiency for an aggregate purchase price of $100 million in cash, with $1 million placed in escrow for post-closing adjustments[145] - The Company has a remaining obligation of up to $5.5 million related to the Immunetrics acquisition, expected to be paid in early 2025[148] - As of November 30, 2024, $30 million remains available for share repurchases under the authorized program, with no shares repurchased in the last three months[149] Tax and Financial Reporting - The effective tax rate increased to 24% for the three months ended November 30, 2024, compared to 19% for the same period in 2023[133] - There were no changes in internal controls over financial reporting that materially affected the Company's internal control during the most recent fiscal quarter[169] Software Development and Amortization - Capitalized computer software development costs were $0.7 million for the three months ended November 30, 2024, compared to $0.9 million for the same period in 2023[154] - Amortization of software development costs amounted to $0.8 million for the three months ended November 30, 2024, up from $0.4 million in 2023[155] Goodwill and Impairment - The Company performed goodwill impairment tests at the reporting unit level, with six reporting units identified as of November 30, 2024[159] - No impairment losses were recorded for intangible assets during the three months ended November 30, 2024 and 2023[161] Insurance and Coverage - The Company obtained a buyer's representation and warranty insurance policy providing up to $10 million in coverage for breaches related to the Pro-ficiency acquisition[147]

Financial Data and Key Metrics - The company has updated its quarterly earnings presentation, which serves as a supplement to the prepared remarks for the Q1 fiscal 2025 financial results [3] - The information discussed may include forward-looking statements involving risks and uncertainties, with words like "believe," "expect," and "anticipate" referring to the company's best estimates as of the call [4] - Management may mention non-GAAP financial measures during the remarks or responses to questions, with reconciliations to the most directly comparable GAAP measures provided [5] Business Line Data and Key Metrics - No specific data or metrics related to individual business lines were provided in the content Market Data and Key Metrics - No specific data or metrics related to individual markets were provided in the content Company Strategy and Industry Competition - No specific details on company strategy or industry competition were provided in the content Management Commentary on Operating Environment and Future Outlook - No specific commentary on the operating environment or future outlook was provided in the content Other Important Information - The conference call is being recorded, and participants are initially in listen-only mode, with a Q&A session to follow the formal presentation [1] - The updated earnings presentation can be accessed on the company's Investor Relations website [3] Q&A Session Summary - No questions or answers were provided in the content, as the Q&A session had not yet commenced at the time of the provided content [1][3]

Earnings Call – Q1 - FY25 January 7, 2025 1 Safe Harbor Statement Except for historical information, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties. Words like "believe," "expect," and "anticipate" mean that these are our best estimates as of this writing, but there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors ...

Core Viewpoint - Simulations Plus reported quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.18 per share, but showing an increase from $0.10 per share a year ago, indicating a -5.56% earnings surprise [1] Financial Performance - The company posted revenues of $18.92 million for the quarter ended November 2024, surpassing the Zacks Consensus Estimate by 1.25%, and up from $14.5 million year-over-year [2] - Over the last four quarters, Simulations Plus has exceeded consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Performance - Simulations Plus shares have increased approximately 4.3% since the beginning of the year, outperforming the S&P 500's gain of 1.6% [3] Future Outlook - The company's earnings outlook is crucial for investors, with current consensus EPS estimates at $0.28 for the coming quarter and $1.11 for the current fiscal year, alongside revenues of $23.46 million and $90.87 million respectively [7] - The estimate revisions trend for Simulations Plus is currently favorable, leading to a Zacks Rank 2 (Buy) for the stock, suggesting expected outperformance in the near future [6] Industry Context - The Computer - Software industry, to which Simulations Plus belongs, is currently ranked in the bottom 44% of over 250 Zacks industries, indicating potential challenges ahead [8] - Another company in the same industry, PTC Inc., is expected to report quarterly earnings of $0.91 per share, reflecting a year-over-year decline of 18% [9]

Exhibit 99.1 Simulations Plus Reports First Quarter Fiscal 2025 Financial Results Total revenue up 31% year-over-year primarily driven by strong software growth RESEARCH TRIANGLE PARK, NC, January 7, 2025 – Simulations Plus, Inc. (Nasdaq: SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended Novem ...

Simulations Plus, Inc (SLP) is slated to release first-quarter fiscal 2025 results on Jan. 7.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar. The Zacks Consensus Estimate for fiscal first-quarter revenues is pegged at $18.7 million, which indicates growth of 28.9% from the year-ago quarter’s reported figure.The consensus mark for earnings is pegged at 18 cents per share, indicating increase of 80% from the prior-year levels. The company’s earnings have surpassed the Zacks Consensus ...

Simulations Plus (SLP) closed the last trading session at $32.74, gaining 6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $51.40 indicates a 57% upside potential.The mean estimate comprises five short-term price targets with a standard deviation of $9.76. While the lowest estimate of $39 indicates a 19.1% increase from the current price level, the most optimistic analyst expects ...

Simulations Plus (SLP) shares ended the last trading session 8.9% higher at $30.04. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 18.8% loss over the past four weeks.The increase in share price can be attributed to strong topline performance. Synergies stemming from acquisitions and organic bases are driving the growth trajectory. New customer wins and increasing sales with existing customers of GastroPlus, Monol ...

Shares of Simulations Plus (SLP) have gained 1.1% over the past four weeks to close the last trading session at $30.70, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $54.50 indicates a potential upside of 77.5%.The average comprises four short-term price targets ranging from a low of $47 to a high of $65, with a standard deviation of $7.94. While the lowest estimate indicates ...

Table of Contents Title of Each Class Trading Symbol(s) Name of Each Exchange on Which Registered Common Stock, par value $0.001 per share SLP NASDAQ Stock Market LLC Large accelerated Filer x Accelerated Filer o Non-accelerated Filer o Smaller reporting company o Emerging growth company o UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended August 31, 2024 or o TRANSIT ...